Velocity Clinical Research Acquires Downtown Women's Health Care (DWHC) and Riverside Clinical Research
March 17, 2021
Velocity Clinical Research, a Durham, North Carolina-based integrated clinical site operator, acquired two U.S. clinical research sites: Downtown Women's Health Care (Denver, CO) and Riverside Clinical Research (northeast Florida). The deals expand Velocity's site footprint to 16 locations, broaden its therapeutic capabilities into renal and hepatic research, and support efforts to diversify patient recruitment for clinical trials.
- Buyers
- Velocity Clinical Research
- Targets
- Downtown Women's Health Care (DWHC), Riverside Clinical Research
- Sellers
- Arthur Waldbaum, MD, Trish Hardee, Bruce Hardee
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
GHO Capital Acquires Velocity Clinical Research
July 15, 2021
Healthcare Services
Global Healthcare Opportunities (GHO) has acquired Durham-based Velocity Clinical Research from NaviMed Capital and other investors. GHO intends to support Velocity’s roll-up strategy of clinical trial sites, expand its integrated site model (including investment in technology and decentralized trial capabilities) and pursue further geographic expansion, including into Europe.
-
Velocity Clinical Research Acquires Meridian Clinical Research
December 15, 2022
Healthcare Services
Velocity Clinical Research, a GHO-backed integrated research site organization, has acquired Meridian Clinical Research for an undisclosed amount. The deal creates the largest dedicated clinical research site organization globally (about 80 sites), expands Velocity's U.S. footprint to 25 states and adds Meridian's network of 35+ sites and experienced investigators and staff.
-
Velocity Clinical Research Acquires TrierHealth
February 22, 2022
Healthcare Services
Durham-based Velocity Clinical Research acquired digital clinical trials platform TrierHealth, bringing its founder Raghu Punnamraju into Velocity as Chief Technology Officer. The acquisition adds Hyderabad-based R&D talent and patient-engagement technology to accelerate Velocity’s move toward decentralized and hybrid clinical trials.
-
Velocity Clinical Research Acquires Impact Research Institute and Liver Institute Northwest Clinical Trials Unit
October 25, 2023
Healthcare Services
Velocity Clinical Research, a Durham, North Carolina–based integrated clinical site network, acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA). The deal expands Velocity's MASH/MASLD (metabolic dysfunction-associated steatohepatitis/steatotic liver disease) capabilities, adds two KOLs (Dr. Kris Kowdley and Dr. Nadege Gunn) and integrates two additional hepatology research sites into its global network.
-
Velocity Clinical Research Acquires VitaLink Research and National Research Institute
September 22, 2021
Healthcare Services
Durham-based Velocity Clinical Research acquired two multi-site clinical research companies—VitaLink Research (six sites in South Carolina) and National Research Institute (five sites in the Los Angeles area)—adding 11 sites to its network. The deal expands Velocity's therapeutic reach and patient recruitment capabilities, creating one of the largest fully integrated site management organizations in the U.S.
-
Velocity Clinical Research Acquires Omega Medical Research and Buynak Clinical Research
June 16, 2020
Healthcare Services
Durham-based Velocity Clinical Research has acquired Omega Medical Research (Providence, Rhode Island) and Buynak Clinical Research (Valparaiso, Indiana), expanding its multi-site footprint to 12 sites across nine states. The deals, together with a strategic partnership with Elite Research Network, are intended to boost Velocity’s capacity for vaccine and COVID-19 treatment trials while adding geographic and therapeutic diversity.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.